Processa Pharmaceuticals, Inc. Current Liabilities
Processa Pharmaceuticals, Inc. (PCSA) had Current Liabilities of $2.39 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:LiabilitiesCurrent · last filed 2026-08-14
- 2026-06-30: Liabilities, Current $2.39M.
- 2026-03-31: Liabilities, Current $1.98M.
- 2025-12-31: Liabilities, Current $2.24M.
- 2025-09-30: Liabilities, Current $1.75M.
| Period end | Liabilities, Current | Liabilities, Current as first filed |
|---|---|---|
| 2026-06-30 | $2.39M 10-Q · filed 2026-08-14 | |
| 2026-03-31 | $1.98M 10-Q · filed 2026-05-07 | |
| 2025-12-31 | $2.24M 10-Q · filed 2026-08-14 | |
| 2025-09-30 | $1.75M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $2.07M 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $1.28M 10-Q · filed 2025-05-08 | |
| 2024-12-31 | $1.53M 10-K · filed 2026-03-18 | |
| 2024-09-30 | $1.22M 10-Q · filed 2024-10-30 | |
| 2024-06-30 | $1.55M 10-Q · filed 2024-08-13 | |
| 2024-03-31 | $1.01M 10-Q · filed 2024-05-10 | |
| 2023-12-31 | $730.58K 10-K · filed 2025-03-20 | |
| 2023-09-30 | $826.07K 10-Q · filed 2023-11-13 | |
| 2023-06-30 | $821.41K 10-Q · filed 2023-08-10 | |
| 2023-03-31 | $2.16M 10-Q · filed 2023-05-15 | |
| 2022-12-31 | $998.56K 10-K · filed 2024-03-29 | |
| 2022-09-30 | $1.19M 10-Q · filed 2022-11-08 | |
| 2022-06-30 | $1.57M 10-Q · filed 2022-08-11 | |
| 2022-03-31 | $1.06M 10-Q · filed 2022-05-12 | |
| 2021-12-31 | $971.02K 10-K · filed 2023-03-30 | |
| 2021-09-30 | $1.23M 10-Q · filed 2021-11-12 | |
| 2021-06-30 | $1.16M 10-Q · filed 2021-08-12 | |
| 2021-03-31 | $1.10M 10-Q · filed 2021-05-13 | |
| 2020-12-31 | $1.22M 10-K · filed 2022-03-30 | |
| 2020-09-30 | $2.66M 10-Q · filed 2020-11-12 | |
| 2020-06-30 | $1.90M 10-Q · filed 2020-08-05 | |
| 2020-03-31 | $1.25M 10-Q · filed 2020-05-15 | |
| 2019-12-31 | $1.19M 10-K · filed 2021-03-25 | |
| 2019-09-30 | $291.68K 10-Q · filed 2019-11-14 | |
| 2019-06-30 | $783.44K 10-Q · filed 2019-08-14 | |
| 2019-03-31 | $724.72K 10-Q · filed 2019-05-14 | |
| 2018-12-31 | $645.70K 10-K · filed 2020-03-06 | |
| 2018-09-30 | $691.19K 10-Q · filed 2018-11-14 | |
| 2018-06-30 | $649.63K 10-Q · filed 2018-08-14 | |
| 2018-03-31 | $2.85M 10-Q · filed 2018-05-21 | |
| 2017-12-31 | $2.60M 10-K/A · filed 2019-04-08 | |
| 2017-09-30 | $115.31K 10-Q · filed 2017-11-20 | |
| 2017-06-30 | $2.49M 10-Q · filed 2017-10-04 | |
| 2017-03-31 | $2.44M 10-Q · filed 2017-10-04 | |
| 2016-12-31 | $97.69K 10-K · filed 2018-04-16 | $2.35M 10-K · filed 2017-09-25 |
| 2016-09-30 | $2.28M 10-Q · filed 2017-09-08 | |
| 2016-06-30 | $2.21M 10-Q · filed 2017-08-30 | |
| 2016-03-31 | $2.17M 10-Q · filed 2017-08-07 | |
| 2015-12-31 | $2.08M 10-K · filed 2017-09-25 | |
| 2015-09-30 | $2.09M 10-Q · filed 2015-12-01 | |
| 2015-06-30 | $2.09M 10-Q · filed 2015-08-19 | |
| 2015-03-31 | $1.72M 10-Q · filed 2015-05-15 | |
| 2014-12-31 | $843.86K 10-K · filed 2017-06-19 | $840.05K 10-K · filed 2015-04-14 |
| 2014-09-30 | $809.47K 10-Q · filed 2014-11-13 | |
| 2014-06-30 | $561.73K 10-Q · filed 2014-08-19 | |
| 2014-03-31 | $784.50K 10-Q · filed 2014-05-14 | |
| 2013-12-31 | $1.12M 10-K · filed 2015-04-14 | |
| 2013-09-30 | $1.31M 10-Q · filed 2013-11-08 | |
| 2013-06-30 | $2.36M 10-Q/A · filed 2013-09-06 | |
| 2012-12-31 | $715.65K 10-K · filed 2014-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |